title: Interleukin-18 primes human basophilic KU812 cells for higher leukotriene synthesis.
abstract: The human basophilic cell line KU812 that is an established tool for studying the function of human basophils, is differentiated into mature basophils by interleukin (IL-3) or other agents. However, whether leukotrienes (LTs)-synthesis is affected by cytokines in KU812 cells remains unknown. KU812 cells were incubated with IL-3, IL-4, IL-6, IL-13 or IL-18 for up to 14 days. The A23187 stimulated- and IgE cross-linked-synthesis of LTC(4) and LTB(4) were measured using an enzyme immunoassay (EIA). The expression of messenger RNA (mRNA) for LT-synthesizing enzymes was examined by reverse transcriptase polymerase chain reaction (RT-PCR), and the expression of 5-lipoxygenase (5-LO) was examined by immunostaining. Incubation with IL-3 (10 ng/ml) and IL-18 (10 ng/ml) induced the expression of 5-LO. A23187stimulated LT-synthesis and IgE cross-linked LT-synthesis were enhanced after incubation with IL-3 or IL-18. These results indicated that IL-3 and IL-18 primed human basophils for higher LT-synthesis. Thus, both IL-3 and IL-18 might be important factors for regulating LT-synthesis during the differentiation of human basophils.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga City 849-8501, Japan. zaitsum@cc.saga-u.ac.jp
authors.forename: Masafumi
authors.initials: M
authors.lastname: Zaitsu
authors.forename: Fumio
authors.initials: F
authors.lastname: Yamasaki
authors.forename: Eiichi
authors.initials: E
authors.lastname: Ishii
authors.forename: Terumi
authors.initials: T
authors.lastname: Midoro-Horiuti
authors.forename: Randall M
authors.initials: RM
authors.lastname: Goldblum
authors.forename: Yuhei
authors.initials: Y
authors.lastname: Hamasaki
mesh_terms: D058927:5-Lipoxygenase-Activating Proteins; D000906:Antibodies / Q000494:pharmacology; D001094:Arachidonate 5-Lipoxygenase / Q000235:genetics / Q000378:metabolism; D001491:Basophils / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D000001:Calcimycin / Q000494:pharmacology; D002352:Carrier Proteins / Q000235:genetics; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D004851:Epoxide Hydrolases / Q000235:genetics; D015870:Gene Expression / Q000187:drug effects; D005982:Glutathione Transferase / Q000235:genetics; D006801:Humans; D007073:Immunoglobulin E / Q000494:pharmacology; D007150:Immunohistochemistry; D020382:Interleukin-18 / Q000494:pharmacology*; D007377:Interleukin-3 / Q000494:pharmacology; D007378:Interleukins / Q000494:pharmacology; D007975:Leukotriene B4 / Q000096:biosynthesis; D017997:Leukotriene C4 / Q000096:biosynthesis; D015289:Leukotrienes / Q000096:biosynthesis*; D008565:Membrane Proteins / Q000235:genetics; D010741:Phospholipases A / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D058927:5-Lipoxygenase-Activating Proteins; C548592:ALOX5AP protein, human; D000906:Antibodies; D002352:Carrier Proteins; D020382:Interleukin-18; D007377:Interleukin-3; D007378:Interleukins; D015289:Leukotrienes; D008565:Membrane Proteins; D012333:RNA, Messenger; D007975:Leukotriene B4; D017997:Leukotriene C4; D007073:Immunoglobulin E; D000001:Calcimycin; D001094:Arachidonate 5-Lipoxygenase; D005982:Glutathione Transferase; D010741:Phospholipases A; D004851:Epoxide Hydrolases; C041116:leukotriene-C4 synthase; C043134:leukotriene A4 hydrolase